Merck, Glenmark Settle Zetia Antitrust Litigation for $70M, Including $23M in Attorney Fees
U.S. District Senior Judge Rebecca Beach Smith of the Eastern District of Virginia approved the final settlement agreement between a class of drug purchasers and pharmaceutical companies, Merck & Co., and Glenmark Pharmaceuticals, which also requires the defendants to pay one-third of the settlement fund in attorney fees, or $23 million, as well as $3.9 million in costs—as requested by plaintiffs’ counsel.